# Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

> **NCT00559988** · PHASE4 · TERMINATED · sponsor: **Biotronik, Inc.** · enrollment: 2718 (actual)

## Conditions studied

- Atrial Fibrillation
- Atrial Flutter
- Stroke
- Embolism, Systemic Arterial
- Major Bleeding

## Interventions

- **DRUG:** Home Monitoring Guided OAC
- **DRUG:** Physician-Directed OAC

## Key facts

- **NCT ID:** NCT00559988
- **Lead sponsor:** Biotronik, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 2718 (ACTUAL)
- **Last updated:** 2017-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00559988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00559988, "Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00559988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*